Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Practice Management

Pfizer-BioNTech COVID-19 Vaccine Elicits Response Against Key Mutation

Diana Ernst, RPh

January 15, 2021

The study was conducted by Pfizer and the University of Texas Medical Branch.

Practice Management

Moderna Increases Production Estimates of COVID-19 Vaccine for 2021

Diana Ernst, RPh

January 7, 2021

According to the Company, 18 million doses have thus far been supplied to the US government.

General Cardiology

Antibody Cocktail for COVID-19 Gets Emergency Use Authorization

Diana Ernst, RPh

December 2, 2020

The investigational treatment from Regeneron consists of 2 potent, virus-neutralizing antibodies.

Heart Failure

Mixed Results for Omecamtiv Mecarbil in Heart Failure Study

Diana Ernst, RPh

October 16, 2020

Findings showed the study met the primary end point of reduction in cardiovascular death or heart failure events.

Stroke

Ticagrelor Under Review for Reduction of Subsequent Stroke in High-Risk Patients

Diana Ernst, RPh

July 17, 2020

The FDA has granted Priority Review of the supplemental New Drug Application for Brilinta (ticagrelor; AstraZeneca), for use in combination with aspirin, to reduce the rate of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.

Dyslipidemia

LDL-C Lowering Combination Therapy Nexlizet Now Available

Diana Ernst, RPh

June 16, 2020

Nexlizet (bempedoic acid and ezetimibe; Esperion) is now available for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Practice Management

NIH Trial Investigating Hydroxychloroquine Plus Azithromycin for COVID-19 Begins

Diana Ernst, RPh

May 26, 2020

The phase 2b trial is expected to include roughly 2000 participants with confirmed SARS-CoV-2 who are experiencing fever, cough, and/or shortness of breath.

Hypertension

Nicardipine HCl Injection Now Available From American Regent

Diana Ernst, RPh

May 14, 2020

An AP-rated and therapeutically equivalent generic of Cardene IV (Chiesi) has been made available by American Regent.

1-in-3 men have some form of cardiovascular disease, according to the American Heart Association. An estimated 2.8 million men experience stroke each year and hypertension is common in younger men. Routine check-ups are important to monitor heart health.

Heart Failure

Omecamtiv Mecarbil Gets Fast Track Status for Heart Failure

Diana Ernst, RPh

May 13, 2020

The FDA has granted Fast Track designation to omecamtiv mecarbil (Amgen) for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF).

Practice Management

COVID-19 mRNA Vaccine Candidates Advancing Through the Pipeline

Diana Ernst, RPh

May 13, 2020

A phase 2 study of Moderna’s vaccine candidate for COVID-19, mRNA-1273, is expected to start shortly following the Food and Drug Administration’s review of the Company’s Investigational New Drug (IND) application.

Next post in Practice Management